Anika Therapeutics (ANIK) Cash Flow Statement

Click line-items for a historical chart and %

Net income	24.46M
Depreciation and amortization
Stock-based compensation expense	2.28M
Deferred income taxes	-571K
Provision for doubtful accounts	52K
Provision for inventory	259K
Accounts receivable	-104K
Inventories	-3.23M
Prepaid expenses, other current and long-term assets	355K
Long-term deposits and other
Accounts payable	-5.39M
Accrued expenses
Deferred revenue	-43K
Income taxes payable	-3.5M
Other long-term liabilities	-61K
Net cash (used in) provided by operating activities	17.96M
Purchase of property and equipment, net	-12.61M
Reduction in purchase price of subsidiary
Net cash used in investing activities	-7.11M
Principal payments on debt
Proceeds from exercise of stock options	988K
Net cash used in financing activities	-23.59M
Exchange rate impact on cash	82K
Decrease in cash and cash equivalents	-12.66M
Cash and cash equivalents at beginning of period	110.71M
Cash and cash equivalents at end of period	98.05M

Entities mentioned with ANIK

View All Entities